An investigational once-daily, single-tablet human immunodeficiency virus (HIV) treatment that combines bictegravir and lenacapavir worked about as well as more complex multi-pill regimens in phase 3 clinical trials designed to keep HIV under control. It also performed similarly to the commonly used combination pill Biktarvy, which contains three HIV medications.

🗳️ Have you tried a once-daily tablet for controlling HIV?

Yes, and it worked for me.

Yes, but it did not work for me.

No, but I am interested in trying one.

No, and I am not interested in trying one.

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with your email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a Member? Log in

Single-tablet HIV treatments like Biktarvy already exist, but they’re not right for everyone. Some people need more complex treatment plans because of drug resistance, medication interactions, or other health conditions. The new combination could offer another one-pill option for people whose treatment can’t easily be simplified today.

How Does This Combo Work?

The investigational pill combines two medicines that are already used in HIV care:

• Bictegravir — An integrase inhibitor that blocks HIV from inserting its genetic material into a person’s cells
• Lenacapavir — A capsid inhibitor that targets the virus’s capsid (protein shell) and interferes with HIV at several points in its life cycle

Together, these medicines are designed to provide a one-pill-a-day option that could replace more complex regimens for some people.

What Did the Studies Find?

In these phase 3 “switch” studies, participants living with HIV who had undetectable viral loads either stayed on their current treatment or switched to the new combo pill.

In the first study, people switched from complex multi-pill regimens to the single tablet. Researchers found that:

• Participants who switched to the single tablet remained virally suppressed at rates similar to those who stayed on their complex regimens.
• Very few people in either group — about 1 percent — experienced viral rebound at 48 weeks.
• No new drug resistance was reported during the study period.
• People who switched reported higher treatment satisfaction.

In the second study, participants switched from Biktarvy to the new tablet. Researchers found that:

• Switching worked about as well as staying on Biktarvy at 48 weeks.
• Viral rebound was uncommon in both groups (again, roughly 1 percent).

What Side Effects Occurred?

Overall, side effects were similar to those seen with other HIV regimens, and most were mild to moderate. Common side effects included:

• Upper respiratory tract infections
• Nasopharyngitis (common cold)
• Diarrhea
• Headache
• Cough
• Joint pain
• High blood pressure

Serious side effects related to the study drug were rare.

Why This Matters for People With HIV

Today’s HIV treatment works very well for many people, but the simplest options don’t work for everyone. If approved by the U.S. Food and Drug Administration (FDA), this single-tablet regimen could become another “one-pill-a-day” choice for people who are currently doing well on treatment, including some who now take multiple pills each day.

However, this single-tablet combo is not yet approved. The company said these phase 3 results will support regulatory filings. Next steps usually include submitting the data to regulators such as the FDA, reviewing the full study results, and deciding whether the treatment can be approved and made available.

If you’re interested in new options like this, your HIV specialist can help you understand whether a switch might make sense for your treatment history, including drug resistance, other medications you take, and possible side effects.

Join the Conversation

On myHIVteam, people share their experiences with HIV, get advice, and find support from others who understand.

Have you tried a single-pill treatment for controlling HIV? Let others know in the comments below.